Announcement on Progress of Wealth Management Product Purchases
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions.
Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Sixth Board of Directors' Sixth Extraordinary Meeting on April 28, 2025, and the 2024 Annual Shareholders' Meeting on June 24, 2025. The proposal on using its own funds for entrusted wealth management was deliberated and approved. It was agreed that the Company and its subsidiaries would collectively use up to RMB 750 million of their own funds for entrusted wealth management. The aforementioned amount can be used on a revolving basis and will be valid for no more than 12 months from the date of approval by the Shareholders' Meeting. The Company's management is authorized to implement relevant matters. In accordance with the above resolution, the Company has selected and purchased relevant wealth management products, and the relevant situation is hereby announced as follows:
I. Main情况 of Wealth Management Products
(1) On May 11, 2026, the Company invested RMB 20 million to purchase a wealth management product from Founder Securities Co., Ltd. (hereinafter referred to as "Founder Securities"), the details of which are as follows:
- Product Name: Founder Securities Xin Xin No. 1 Single Asset Management Plan
- Product Code: DZXX01
- Main Investment Scope of the Product: (1) Fixed-income assets: government bonds, local government bonds, policy bank bonds, central bank bills, financial bonds, corporate bonds, medium-term notes, short-term commercial paper, ultra-short-term commercial paper, privately placed debt financing instruments (PPN), asset-backed securities, asset-backed bills, bond funds, money market funds, bank deposits, and other standardized fixed-income assets such as interbank certificates of deposit. (2) Equity assets: stocks legally issued by the Beijing Stock Exchange. (3) Futures and derivatives: treasury bond futures. (4) This plan can participate in bond repurchase and reverse repurchase business. (5) Private asset management products: asset management plans of insurance companies and their subsidiaries.
- Expected annualized yield: 3.0% + excess return
- Product income start date: May 13, 2026
- Product maturity date: Redemption is available on the 15th of each month, 6 months after the lock-up period.
(2) On April 23, 2026, the Company invested RMB 30 million to purchase a wealth management product from GF Securities Co., Ltd. (hereinafter referred to as "GF Securities"), the details of which are as follows:
- Product Name: Yuecai Trust · Suixin Yihao No. 6 Collective Fund Trust Plan
- Product Code: YCOKBM
- Main Investment Scope of the Product: (1) Trust industry guarantee fund; (2) The remaining funds will be fully invested in bonds, asset-backed securities, asset-backed bills, bond repurchase, money market funds, bond funds, senior tranches of structured funds, cash, bank deposits, certificates of deposit, interbank certificates of deposit, large-denomination transferable certificates of deposit, fixed-income wealth management products/asset management plans with underlying assets as standardized debt claims, or other standardized debt products permitted for investment by laws, regulations, or policies, and income certificates issued with the approval or filing of financial regulatory authorities. Investment in asset-backed bills, structured funds, and LOF funds requires confirmation from the custodian before relevant transactions can be conducted.
- Expected annualized yield: 2.50%
- Product income start date: April 24, 2026
- Product maturity date: October 20, 2026